Floatz logo

Irinotecan

Alveolar Soft Part Sarcoma

Taiho Pharmaceutical Co., Ltd.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Alveolar Soft Part Sarcoma cohort.

Asset / SponsorPhaseRating
Bms-907351
National Cancer Institute (NCI)
Phase 2CCC
Zoledronate
University of Florida
Phase 1/2CC
Fludarabine
Canadian Cancer Trials Group
Phase 1CC
Tas-115
Taiho Pharmaceutical Co., Ltd.
Phase 1CC
PIMITESPIB
Taiho Pharmaceutical Co., Ltd.
Phase 1CC

View all 18 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →